The partnership will develop new technologies to improve cell therapies for cancer patients. More: GSK, Lyell join forces for cancer cell therapies Source: News
read moreThere are no approved drugs at current for preventing or slowing disease progression. More: Sprifermin shows promise in knee osteoarthritis Source: News
read moreTheragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations. More: Theragnostics, GE Healthcare announce prostate cancer diagnostic partnership Source: News
read moreSamsung Bioepis has announced real-world data from the drug. More: Benepali bags positive psoriasis results Source: News
read moreWhen generic challengers come for a branded med’s patent, drugmakers have in the past chosen to pony up and stall the rivals with an anticompetitive pact better known as “pay for delay.” In an effort to keep drug prices down,
read moreAs Takeda folds in Shire, two of the rare disease specialist’s former top leaders have found themselves a new home at Nestlé skin health spinoff Galderma. Flemming Ornskov, Shire’s most recent CEO who orchestrated the Baxalta buyout, will lead Galderma
read more© 1994 - 2026 B.M. Pharmaceuticals